(Q28214486)

1

0 references

C M Perry

2

0 references

Keri Wellington

1

0 references

Caroline M. Perry

https://scigraph.springernature.com/pub.10.2165/00023210-200115080-00007

2

0 references

language of work or name

English

0 references

publication date

2001

0 references

published in

CNS Drugs

0 references

volume

15

0 references

page(s)

643-69

0 references

643-669

0 references

issue

8

0 references

exact match

0 references

cites work

Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200115080-00007

Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200115080-00007

A case report of venlafaxine toxicity.

21 January 2018

1 reference

12 December 2020

Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology

1 reference

12 December 2020

2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity

1 reference

12 December 2020

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

1 reference

12 December 2020

Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy

1 reference

12 December 2020

Strategies and tactics in the management of maintenance treatment for depressed patients

1 reference

12 December 2020

A pharmacoeconomic evaluation of major depressive disorder (Italy)

1 reference

12 December 2020

Antidepressant options: venlafaxine in perspective

1 reference

12 December 2020

Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.

1 reference

12 December 2020

Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine

1 reference

12 December 2020

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

12 December 2020

Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.

1 reference

12 December 2020

Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens.

1 reference

12 December 2020

Serotonin syndrome in combined moclobemide and venlafaxine ingestion

1 reference

12 December 2020

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

1 reference

12 December 2020

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations

1 reference

12 December 2020

Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor

1 reference

12 December 2020

Safety and tolerance profile of venlafaxine.

1 reference

12 December 2020

Possible delayed venlafaxine withdrawal reaction: two case reports

1 reference

12 December 2020

Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine

1 reference

12 December 2020

Status of treatment of depression

1 reference

12 December 2020

Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients

1 reference

12 December 2020

Venlafaxine: a structurally unique and novel antidepressant.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol

1 reference

12 December 2020

Treatment of venlafaxine discontinuation symptoms with ondansetron

1 reference

12 December 2020

Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein

1 reference

12 December 2020

Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers

1 reference

12 December 2020

Venlafaxine-induced serotonin syndrome with relapse following amitriptyline

1 reference

12 December 2020

ASHP therapeutic position statement on the recognition and treatment of depression in older adults: American Society of Health-System Pharmacists

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk.

1 reference

12 December 2020

Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite

1 reference

12 December 2020

Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients

1 reference

12 December 2020

Venlafaxine withdrawal reactions

1 reference

12 December 2020

Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms

1 reference

12 December 2020

Medicine Cabinet: Drug treatment of depression.

1 reference

12 December 2020

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans

1 reference

12 December 2020

Cardiovascular safety in depressed patients: focus on venlafaxine

1 reference

12 December 2020

Effect of venlafaxine on the pharmacokinetics of terfenadine.

1 reference

12 December 2020

Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety

1 reference

12 December 2020

Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man.

1 reference

12 December 2020

Venlafaxine withdrawal reactions.

1 reference

12 December 2020

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

1 reference

12 December 2020

Serotonin syndrome from venlafaxine-tranylcypromine interaction

1 reference

12 December 2020

Lack of beta adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine.

1 reference

12 December 2020

The place for the tricyclic antidepressants in the treatment of depression

1 reference

12 December 2020

Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.

1 reference

12 December 2020

Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers

1 reference

12 December 2020

The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database

1 reference

12 December 2020

Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects

1 reference

12 December 2020

Population-based care of depression: effective disease management strategies to decrease prevalence

1 reference

12 December 2020

Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.

1 reference

12 December 2020

Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam.

1 reference

12 December 2020

Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines

1 reference

12 December 2020

Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders

1 reference

12 December 2020

Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics.

1 reference

12 December 2020

Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine

1 reference

12 December 2020

Serotonin syndrome induced by administration of venlafaxine and phenelzine

1 reference

12 December 2020

Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs

1 reference

12 December 2020

Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.

1 reference

12 December 2020

Effect of venlafaxine on the pharmacokinetics of risperidone.

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group

1 reference

12 December 2020

Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide

1 reference

12 December 2020

Venlafaxine:a novel antidepressant compound

1 reference

12 December 2020

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans

1 reference

12 December 2020

Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

Venlafaxine withdrawal syndrome

1 reference

12 December 2020

Venlafaxine. A review of its pharmacology and therapeutic potential in depression

1 reference

12 December 2020

Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion

1 reference

12 December 2020

North of England evidence-based guideline development project: summary version of guidelines for the choice of antidepressants for depression in primary care

1 reference

12 December 2020

Withdrawal reactions associated with venlafaxine

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine

1 reference

12 December 2020

Antidepressant discontinuation: a review of the literature.

1 reference

12 December 2020

Serotonin syndrome secondary to phenelzine-venlafaxine interaction

1 reference

12 December 2020

Rational drug use in the treatment of depression

1 reference

12 December 2020

Mechanism of action of antidepressant medications

1 reference

12 December 2020

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

12 December 2020

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

12 December 2020

Venlafaxine induced serotonin syndrome occurring after abstinence from phenelzine for more than two weeks

1 reference

12 December 2020

The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population.

1 reference

12 December 2020

Cardiovascular and neurological toxicity of venlafaxine

1 reference

12 December 2020

Breast enlargement during chronic antidepressant therapy

1 reference

12 December 2020

The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine

1 reference

12 December 2020

Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine

1 reference

12 December 2020

Effect of venlafaxine on the pharmacokinetics of alprazolam.

1 reference

12 December 2020

Long-term nature of depression

1 reference

12 December 2020

The long-term treatment of depression

1 reference

12 December 2020

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

1 reference

12 December 2020

A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression.

1 reference

12 December 2020

Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man

1 reference

12 December 2020

A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression

1 reference

12 December 2020

Antidepressant Use in the Elderly

1 reference

12 December 2020